BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Irafamdastat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Irafamdastat\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07837115-11183@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20261219
DTEND;VALUE=DATE:20261220
SUMMARY:Irafamdastat: Phase 1 readout est. (NCT07837115)
DESCRIPTION:Irafamdastat\, phase 1.\nStudy: A Study to Assess the Relative 
 Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect
  on the Pharmacokinetics of Irafamdastat in Healthy Adult Participants\nEs
 timated primary completion: 19 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/irafamdastat#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07837115
URL:https://assetmemo.bio/drug/irafamdastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700329-11183@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270224
SUMMARY:Irafamdastat: Phase 1 readout est. (NCT07700329)
DESCRIPTION:Irafamdastat\, phase 1.\nStudy: A Study to Evaluate the Blood L
 evels\, Safety\, and Tolerability of BMS-986368 in Healthy Chinese Partici
 pants\nEstimated primary completion: 23 February 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/irafamdastat#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07700329
URL:https://assetmemo.bio/drug/irafamdastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06782490-11183@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20270526
DTEND;VALUE=DATE:20270527
SUMMARY:Irafamdastat: Phase 2 readout est. (NCT06782490)
DESCRIPTION:Irafamdastat\, phase 2\, Multiple Sclerosis.\nStudy: A Study to
  Evaluate the Efficacy\, Safety and Tolerability of BMS-986368 in Particip
 ants With Multiple Sclerosis Spasticity\nEstimated primary completion: 26 
 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/irafamdasta
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 782490
URL:https://assetmemo.bio/drug/irafamdastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704840-11183@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Irafamdastat: Phase 2 readout est. (NCT07704840)
DESCRIPTION:Irafamdastat\, phase 2.\nStudy: A Pilot Study to Evaluate the E
 fficacy\, Safety and Tolerability of BMS-986368\, a FAAH/MAGL Inhibitor\, 
 in Participants With Post-Stroke Spasticity (The STIPS Study)\nEstimated p
 rimary completion: June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/irafamdastat#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07704840
URL:https://assetmemo.bio/drug/irafamdastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06808984-11183@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Irafamdastat: Phase 2 readout est. (NCT06808984)
DESCRIPTION:Irafamdastat\, phase 2.\nStudy: Study to Evaluate the Efficacy\
 , Safety\, and Tolerability of BMS-986368\, for the Treatment of Agitation
  in Participants With Alzheimer's Disease\nEstimated primary completion: 2
 6 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iraf
 amdastat#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06808984
URL:https://assetmemo.bio/drug/irafamdastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
